How blocking a single molecule can improve the quality of life for sufferers of rheumatoid arthritis.

Fighting Arthritis: the development of anti-TNF therapies

Professor Sir Marc Feldmann and Professor Sir Ravinder Maini talk about how they discovered that blocking a single molecule can improve the quality of life for sufferers of rheumatoid arthritis.

The two professors have been named winners of a 2014 Canada Gairdner Award, one of the world's most prestigious awards for medical research. Their discovery of an antibody-based treatment, or 'anti-TNF' therapy, for the treatment of rheumatoid arthritis and other inflammatory diseases has transformed the lives of great numbers of patients.

Previously, they have also jointly received the Crafoord Prize by The Royal Swedish Academy of Sciences, The Lasker prize for Clinical Research, the Dr Paul Jannsen Award for Biomedical Research, and the Ernst Schering Prize, among other honours.

The Kennedy Institute of Rheumatology was formed in 1965 as the Mathilda and Terrence Kennedy Institute of Rheumatology. The Institute is still closely linked to the Kennedy Trust for Rheumatology Research (KirTrust) which became a separate entity after the Institute merged with Imperial College London. The Institute joined Oxford University in August 2011, becoming part of the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS).